DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by MML Investors Services LLC

MML Investors Services LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 17.0% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 36,235 shares of the medical device company's stock after buying an additional 5,260 shares during the period. MML Investors Services LLC's holdings in DexCom were worth $2,818,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Versant Capital Management Inc bought a new position in shares of DexCom during the 4th quarter valued at $25,000. Private Trust Co. NA lifted its stake in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares during the period. TD Private Client Wealth LLC lifted its stake in shares of DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares in the last quarter. Larson Financial Group LLC increased its holdings in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new position in DexCom in the 4th quarter worth about $38,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on DXCM shares. Canaccord Genuity Group raised their price target on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and raised their price target for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and upped their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Finally, Mizuho started coverage on shares of DexCom in a research report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price target on the stock. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, DexCom has an average rating of "Moderate Buy" and a consensus target price of $99.00.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded up $0.08 during trading on Wednesday, hitting $71.38. The stock had a trading volume of 2,859,104 shares, compared to its average volume of 4,202,465. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $132.26. The stock has a market capitalization of $27.99 billion, a price-to-earnings ratio of 49.92, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. The stock has a 50-day simple moving average of $72.35 and a two-hundred day simple moving average of $76.70.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach sold 14,076 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the sale, the chief operating officer now owns 313,497 shares of the company's stock, valued at $22,063,918.86. The trade was a 4.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares in the company, valued at approximately $26,183,401.02. The trade was a 8.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock valued at $4,734,384 in the last ninety days. 0.32% of the stock is currently owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.